POZEN, Inc. - Conference Presentation Calls

POZEN Inc. announced earnings results for the third quarter and nine months ended September 30, 2009. The company reported a net income attributable to common stockholders of $6.7 million, or $0.22 per share on a diluted basis, for the third quarter of 2009, compared to net loss attributable to common stockholders of $7.9 million, or $0.26 per share on a diluted basis, for the third quarter of 2008. For the third quarter of 2009, the company reported revenue of $14.3 million resulting from a $10 million milestone payment for the New Drug Application (NDA) filing for VIMOVO(TM) (naproxen/esomeprazole magnesium), the amortization of upfront payments received pursuant to the collaboration agreement with AstraZeneca of $3.1 million and royalties of $1.2 million on sales of Treximet(R) (sumatriptan and naproxen sodium). Revenue for the third quarter ended September 30, 2008 totaled $11.1 million, resulting from the amortization of upfront payments received pursuant to the collaboration agreements with AstraZeneca and GlaxoSmithKline of $3.2 million, $7.5 million of revenue for development work, and $0.4 million of royalties on sales of Treximet. The company reported a net loss attributable to common stockholders of $1.1 million, or $0.04 per share on a diluted basis, for the nine month period ended September 30, 2009, compared to a net loss attributable to common stockholders of $1.9 million, or $0.06 per share on a diluted basis, for the same period in 2008. For the nine months ended September 30, 2009, the company reported revenue of $28.0 million compared to $52.1 million for the same period in 2008. The decrease in revenue was primarily due to $14.6 million less development revenue in 2009 and $10.0 million less in milestone payments in 2009.

POZEN, Inc. expected to Report Fiscal Year 2009 Results on February 22, 2010. This event was calculated by Capital IQ (Created on October 28, 2009).